|
|
HBPRCA
Annual Scientific Meeting 2008
celebrating 30 years
|
The meeting will run from Wednesday 3 December to Friday 5 December
2008.
A program
outline
| Wednesday
3 December 2008 |
- Human and Animal
Devices Workshop Clinical and Basic Research
- Annual General Meeting,
with drinks
|
Thursday 4 December 2008 |
- Oral presentations
- A Doyle Lecture
Assoc. Prof David Sinclair
- Colin I Johnston
Lecturer Assoc. Prof Bruce Neal
- BHS Nominee Presentation
- Moderated Poster
Session (Student Finalists)
- Early Career Oral
Presentation Finalists
- 30th Anniversary
Conference Dinner
|
Friday 5 December 2008 |
- Oral presentations
- Foundation Fellow
Presentation Dr Alyson Miller
- Student Oral Presentation
Finalists
- RD Wright Lecture Prof Carlos Ferrario
- Moderated Poster
Session (Early Career Finalists)
- Awards Ceremony
|
Professor
Carlos Ferrario
Hypertension & Vascular Research Center
Wake Forest University Health Sciences, USA
RD Wright Lecturer
 |
Research
Description:
Cardiovascular Medicine
Hemodynamics of Hypertension
Hormonal Regulation of Blood Pressure
Vascular Disease |
Current
Research:
Elucidation of the mechanisms of hypertensive vascular disease
by combining laboratory efforts with clinical investigation
utilizing molecular, genetic, and physiological approaches
to the characterization of cardiac and blood vessel remodeling;
Study of the function of angiotensin peptides, with special
emphasis on angiotensin-(1-7) in the regulation of blood pressure;
Analysis of the mechanism of action of antihypertensive drugs
such as angiotensin converting enzyme inhibitors and angiotensin
II antagonists in reversing the cardiac and vascular sequelae
of hypertension and the metabolic syndrome.
Dr. Ferrario has published 400 papers to-date in the field
of hypertension and vascular disease. He serves as officer
and member of many professional societies and has been bestowed
multiple national and international awards.
He is the Founder of the Consortium for Southeastern Hypertension
Control (COSEHC), an organization which has pioneered medical
and educational efforts directed to reduce cardiovascular
deaths in the South. |
Associate Professor David
Sinclair
Department of Pathology
Harvard Medical School, USA
Austin Doyle Lecturer
 |
Research Interests
In the past 10 years there has been a paradigm shift in our
understanding of aging. Until the 1990s, almost all researchers
believed that the aging process was too complex to find single
genes or drugs that could slow the process. Then geneticists
began to uncover mutations that could dramatically extend
the lifespan of laboratory organisms such as yeast, worms,
flies, and mice. How could this be? We now know that the rate
of aging is not predetermined. |
It is naturally regulated
by a few critical genes. One of the key regulators of aging
that we study is a gene called SIR2. Extra copies of the
SIR2 gene extend lifespan of diverse organisms, from yeast
to flies. The gene family, known as the "sirtuins" seems
to have evolved about one billion years ago to increase
an organism's defenses during times when food was scarce.
We use a variety of models and methods to understand sirtuin
function and how to extend lifespan, including yeast, nematode
worms, mammalian cell culture, biochemistry, and transgenic/knockout
mice. We have identified small molecules that extend lifespan
by activating sirtuins and are testing their ability to
treat diseases including cancer, heart disease, diabetes,
and neurodegeneration.
Our goals are:
(i) To have a comprehensive understanding of sirtuin regulation
and function in mammals
(ii) To have tested whether it is possible to extend the
lifespan of a mouse by modulating the sirtuins or a sirtuin
regulator
(iii) To more fully understand which tissues are important
for the regulation of mammalian lifespan.
(iv) To discover whether it is possible to create a molecule
that can activate longevity pathways and thereby treat age-related
diseases such as cancer, cardiovascular disease, neurodegeneration,
and diabetes.
In a large article
in Nature we showed that the red wine polyphenol, resveratrol,
could prevent the development of cardiovascular disease,
diabetes, hepatic steosis and cancer in obese mice, with
no decrease in body weight. |
Associate Professor Bruce
Neal
The George Institute for International Health, Australia
Colin I Johnston Lecturer
 |
Bruce Neal,
MB ChB, PhD, FRCP, FAHA is a Senior Director at The George
Institute for International Health, Associate Professor of
Medicine at The University of Sydney and Chair of the Australian
Division of World Action on Salt and Health. Bruce completed
his medical training at Bristol University in the UK in 1990
and spent four years in clinical posts. |
| Prior to
taking up his position at the Institute in 1999, he worked
as an epidemiologist at the Clinical Trials Research Unit
in Auckland, New Zealand, where he completed a PhD in Medicine.
Bruce has a specific and longstanding interest in blood pressure
and has done important studies of both drug and non-drug interventions.
His particular area of expertise is in large-scale trials,
cohort studies and meta-analyses and he has worked hard to
extend the reach of these projects worldwide, with a particular
effort to include developing countries in the Asia-Pacific
region |
|
|